iSpeak Blog

The Pharma CAPEX Paradox: Companies May Have the Capital—But Do They Have the Execution Capacity?

Mary Chapman
corporate-manager-talking-group-manual-workers-while-having-staff-meeting-factory

The pharmaceutical industry is entering an unprecedented era of capital investment, with major programs underway to expand manufacturing capacity, modernize facilities, strengthen supply-chain resilience and accelerate the adoption of next-generation technologies. Yet as investment increases, critical question is emerging: does the industry have sufficient execution capability to deliver these programs successfully?

Pharmaceutical companies are investing at significant scale. The next challenge is ensuring they have the capability to turn that investment into operational reality.

The capital is coming. Across the pharmaceutical industry, organizations are making significant investments in manufacturing capacity, facility expansion, advanced technologies, supply-chain resilience, and next-generation production capabilities. Yet these capital investments raise a second question that often receives far less attention: how can these assets be transitioned into sustained operational value?

Who Is Going to Deliver It?

The pharmaceutical industry does not simply need more engineers, contractors, equipment suppliers, or project managers. It needs experienced professionals who can make complex programs work—people who understand how thousands of technical, commercial, regulatory and operational decisions interact throughout the project lifecycle.

That distinction is important. There is a significant difference between capacity and capability.

A supplier may have the capacity to take on another project. A contractor may have the resources to mobilize. A project team may have the right number of people on its organization chart.

But do they have the experience to recognize the risks before they become schedule delays or cost overruns?

Can they effectively manage the interfaces between design, procurement, construction, commissioning, qualification and operations?

Can they make sound, timely decisions when the project inevitably moves away from the original plan?

In a high-capital, highly regulated pharmaceutical environment, the answer to these questions often determine whether a project merely reaches completion or ultimately delivers its intended business value.

The Execution Gap

The pharmaceutical industry has become exceptionally good at securing capital for strategic investments.

The greater challenge is often transforming that capital into consistent, predictable execution.

The industry is competing for many of the same limited pool of engineering, construction, commissioning, qualification and project-management professionals across an increasingly busy global market. At the same time, projects are becoming more complex, technology is evolving rapidly, and expectations around speed, resilience and operational readiness continue to increase.

This dynamic is creating an emerging execution gap.

The execution gap is not simply a question of resource availability. Rather, it reflects the difference between having sufficient resources and having the sufficient experience capability to deliver successful outcomes.

Experience is difficult to scale quickly.

A project manager who has successfully delivered one major capital program is not automatically interchangeable with someone who has delivered ten. A supplier who can manufacture a piece of equipment is not necessarily a supplier who understands how that equipment will interface with the wider facility, automation strategy, qualification requirements and operational model.

Likewise, adding more people to a project team does not necessarily increase its ability to execute.

Sometimes it simply increases the number of interfaces that need to be managed.

Capacity Is Not Capability

This distinction becomes particularly important during supplier selection.

Traditional procurement processes understandably focus on technical compliance, commercial competitiveness, available capacity and contractual commitments.

But for complex capital projects, another question deserves equal attention:

Has this supplier demonstrated the capability to deliver this type of project successfully in the environment in which it will operate?

That means looking beyond whether a supplier can provide the equipment, service or construction resource.

It means understanding the following:

  • Have they delivered comparable projects?
  • Do they understand the interfaces with other suppliers?
  • Can they manage design changes without destabilizing the program?
  • Do they understand commissioning and qualification requirements early enough?
  • Can they provide experienced people throughout the project lifecycle?
  • Do they understand the operational requirements of the end user?
  • Can they identify emerging risks before they become expensive problems?

The lowest-cost supplier is not necessarily the lowest-cost solution.

A supplier that creates uncertainty elsewhere in the program can ultimately impose a far greater cost through redesign, delays, additional commissioning effort, change control and operational disruption.

Supplier certainty therefore needs to become part of project strategy—not simply a procurement consideration.

The Interface Problem

One of the most underestimated risks in complex capital projects is the space between disciplines.

  • Engineering may be progressing according to plan
  • Procurement may be progressing according to plan
  • Construction may be progressing according to plan
  • Commissioning may be progressing according to plan
  • Operations may be preparing for handover

And yet the project can still be headed towards trouble.

Why?

Because major project failures rarely respect organizational boundaries, the problem may sit:

  • Between equipment and automation
  • Between design and construction
  • Between supplier documentation and qualification
  • Between commissioning and operations
  • Between what was technically specified and what the manufacturing team actually needs

These interfaces require experienced people who can see the whole system, rather than optimizing an individual workstream.

The lesson is straightforward: project governance should focus not only on whether individual packages are on track, but on whether the interfaces between those packages are creating hidden risk.

What the Pharmaceutical Industry Can Learn from the Semiconductor Industry

The author’s perspective on this challenge has been shaped by experience across both the semiconductor and pharmaceutical industries.

The industries are very different, but they share an important characteristic:

The cost of getting major capital projects wrong is enormous.

Semiconductor manufacturing has operated for decades in an environment characterized by high capital intensity, rapidly changing technology, demanding schedules and highly interconnected supply chains.

This has created a strong emphasis on repeatability, standardization, early supplier involvement, disciplined interfaces and learning from previous projects.

Pharmaceutical industry can learn from that approach.

Not by copying semiconductor methodologies wholesale, the regulatory, quality and patient-safety requirements of pharmaceutical manufacturing are fundamentally different, but by asking a broader question:

What elements of high-tech project delivery can be adapted to increase execution certainty?

Three areas stand out.

1. Standardize where it makes sense

Every project does not need to be designed from scratch.

Where facilities, equipment platforms, utilities, automation architectures or packaging technologies can be standardized, the organization can reduce engineering effort, shorten decision cycles and create opportunities to reuse knowledge.

Standardization also creates something even more valuable:

Organizational learning.

When teams repeatedly deliver similar solutions, lessons from one project can be embedded into the next.

The objective is not to eliminate innovation.

It is to avoid reinventing everything around the innovation.

2. Engage suppliers earlier

Supplier involvement is often treated as a procurement activity that begins after the project has already been substantially defined.

For complex programs, that can be too late.

The suppliers who will ultimately design, manufacture, install, integrate and support critical systems often possess knowledge that can materially influence the project strategy.

Early engagement can expose constraints before they become commitments.

It can identify long-lead items.

It can challenge assumptions.

It can highlight integration risks.

And it can help the project team understand where genuine capacity and capability exist in the market.

The goal is not to give suppliers control of the project.

It is to bring their expertise into the project early enough for it to create value.

3. Build repeatable delivery models

If a pharmaceutical organization is going to deliver multiple major capital programs, each project should not be treated as an isolated event.

The organization should ask:

What are we learning that can make the next project faster, safer and more predictable?

This means deliberately capturing knowledge across project definition, design, procurement, construction, commissioning, qualification and operational readiness.

It also means developing relationships with experienced delivery partners that can build organizational knowledge over multiple programs.

A project team should not have to relearn the same lessons every time capital is approved.

Governance should enable decisions—not slow them down

There is another area where execution capability becomes critical: governance.

Complex pharmaceutical projects can generate enormous amounts of information.

Schedules, risk registers, change controls, procurement reports, design reviews, cost forecasts, validation plans and technical documentation can create the appearance of control.

But governance is only valuable if it enables the right decisions at the right time.

Strong governance should answer three questions quickly:

  • What has changed?
  • Why does it matter?
  • What decision is required?

This sounds simple.

In practice, it requires experienced leaders who can distinguish between noise and material risk.

A mature governance model should therefore not be measured by the number of meetings or reports it produces.

It should be measured by the quality and speed of the decisions it enables.

From Capital Investment to Execution Capability

The pharmaceutical industry has an enormous opportunity.

The investment being made today can create manufacturing capacity that supports patients, strengthens supply chains and enables the next generation of medicines.

But approving capital is only the beginning.

The real value is created when that capital becomes a functioning, qualified and operational manufacturing capability.

That requires more than money.

It requires experienced people.

It requires capable suppliers.

It requires strong interfaces.

It requires repeatable delivery models.

It requires disciplined governance.

And it requires organizations to treat execution capability as a strategic asset rather than an operational resource that can simply be added when a project starts.

The pharmaceutical industry has historically focused heavily on what it needs to build.

As capital programs accelerate, it may need to focus equally on how it will build them—and, critically, who has the experience to make them succeed.

The next competitive advantage in pharmaceutical capital delivery may therefore not be another technology.

It may be the ability to execute consistently at scale.

Because capital creates the opportunity.

Capability turns it into reality.


Disclaimer

iSpeak blog posts provide an opportunity for the dissemination of ideas and opinions on topics impacting the pharmaceutical industry. Ideas and opinions expressed in iSpeak blog posts are those of the author(s) and publication thereof does not imply endorsement by ISPE.

ISPE members: View ISPE Communities of Practice. 
Not an ISPE member? Join today.

Submit Your Best Content to ISPE

ISPE’s official blog, iSpeak accepts contributions from our Members and professionals in the pharma industry.  

What We Look For 

References